DB19105InvestigationalNucleic Acid Based Therapies
Tivanisiran is under investigation in clinical trial NCT03108664 (HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)).
- Mechanism
- Curator reviewed
Pharmacologically active on Transient receptor potential cation channel subfamily V member 1
- Also known as
- Rna, (a-a-g-c-g-c-a-u-c-u-u-c-u-a-c-u-u-c-a), complex with rna (u-g-a-a-g-u-a-g-a-a-g-a-u-g-c-g-c-u-u) (1:1)
- Code names
- SYL-1001
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Tivanisiran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account